Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry

Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI starting March 2015 over an 18 month enrollment period. Antithrombotic therapy selection will be at the discretion of the treating physician. An integral feature of this study is the use of a smartphone based survey to capture physician and patient perspectives regarding antithrombotic therapies following PCI. Survey derived patient treatment concerns, perceived need and affordability will be used to calculate the risk of non-adherence. Subjective risk for ischemic or bleeding events will be correlated with previously validated risk scores as well as actual event rates observed in follow-up at 1,6 or 12 months post-PCI. Endpoints The primary efficacy endpoint will be major adverse cardiac and cerebrovascular events (MACCE), a composite occurrence of death, non-fatal myocardial infarction, stroke, stent thrombosis (ST) and clinically-driven tar...
Source: American Heart Journal - Category: Cardiology Source Type: research